The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of chemoradiation with weekly panitumumab following neoadjuvant chemotherapy and pelvic lymph node dissection as an organ preserving treatment of invasive bladder cancer.
 
Elisabeth E. Fransen van de Putte
No Relationships to Disclose
 
Floris J. Pos
No Relationships to Disclose
 
Barry Doodeman
No Relationships to Disclose
 
Bas W.G. van Rhijn
Consulting or Advisory Role - Astellas Pharma (Inst)
 
Elsbeth van der Laan
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); Roche/Genentech (Inst)
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis
 
Jan M. Kerst
No Relationships to Disclose
 
Simon Horenblas
No Relationships to Disclose
 
Andre M. Bergman
Research Funding - Amgen (Inst)